NCT07502560招募中4 期
A Randomized, Placebo Controlled, Observer-blind, Phase IV Pragmatic Trial to Evaluate the Effect of Recombinant Zoster Vaccine (Shingrix) on Incident Dementia Diagnosis in an Older Adult Population Aged ≥76 Years in Finland
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 33,609
- 试验地点
- 8
研究概览
简要总结
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Data will be collected in an observer-blinded fashion.
入排标准
- 年龄范围
- 76 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Citizens living permanently in Finland, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure. Informed consent will include consent to access health register data for participants.
- •Age 76 years or older at the time of signing the informed consent.
排除标准
- •Prior receipt of a Herpes Zoster (HZ) vaccine.
- •History of dementia diagnosis prior to enrolment, including confirmed cases or those under investigation. This includes:
- •History of a confirmed clinical diagnosis of dementia prior to enrolment.
- •Prior or current use of medications intended to treat dementia.
- •Current or recent history of cognitive assessments for any memory deficit or suspected dementia before enrolment including investigations that are ongoing or that were inconclusive (but not those for which dementia was conclusively ruled out); mild cognitive impairment on its own without any other information to indicate cognitive decline or dementia will not result in exclusion.
- •Severely immunocompromised individuals.
- •Concurrently participating in another clinical trial, in which the participant has been or will be exposed to an investigational product or ongoing participation in trials focused on preventive dementia interventions.
- •Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.
- •Living in a nursing facility.
研究者
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
3 期
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)Herpes ZosterNCT07293065MAXVAX Biotechnology Limited Liability Company12,000
Enrolling By Invitation
1 期
A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)NCT07633197Changchun BCHT Biotechnology Co.120
尚未招募
2 期
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and AboveNCT07354659CSPC Megalith Biopharmaceutical Co.,Ltd.800
招募中
不适用
Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail PatientsNCT07321808Fondazione IRCCS Policlinico San Matteo di Pavia300
进行中（未招募）
2 期
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and OlderNCT07311148Guangzhou Patronus Biotech Co., Ltd.840